Lucas de Sá Grassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucas de Sá Grassi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Gerly Anne Castro Brito
Department of Physiology and Pharmacology, Faculty of Medicine Federal University of Ceará Fortaleza Ceará Brazil
1 shared publication - José Wilson Benevides de Mesquita Neto
Departamento de Oncologia Digestiva. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Departamento de Oncologia Digestiva, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil
1 shared publication - Karoline Sabóia Aragão
Department of Physiology and Pharmacology and Institute of Biomedicine, School of Medicine, Federal University of Ceara, Rua Cel. Nunes de Melo, 1315, Fortaleza, CE, Brazil
1 shared publication - Leandro Linhares Leite
Hospital de Clínicas de Porto Alegre, Brazil
1 shared publication - Lorena Guimaraes Nunes
Federal University of Ceará (UFC)
1 shared publication - Marcellus Henrique Loiola Ponte Souza
Federal University of Ceará
1 shared publication
Latest Publications
- 1 August 2014
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (4) , 711-720
Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model
Nonalcoholic steatohepatitis (NASH) has been associated with irinotecan (IRI)-based cancer chemotherapy regimens. The purpose of this study was to propose and test a consistent model of IRI-induced NASH, filling a gap in the medical literature. Swiss male mice were distributed in groups (n = 8) and injected with saline (5 mL/kg, i.p.; control) or IRI (25, 50, 75 or 100 mg/kg, i.p.) thrice a week for 7 weeks. Blood samples were collected to measure the serum concentrations of proteins, alanine and aspartate aminotransferases (ALT and AST). Each week animals were euthanized, and the livers were submitted to myeloperoxidase (MPO) assay, lipid dosage, immunohistochemistry for inducible nitric oxide synthase (iNOS), TNF-α and interleukin-1β (IL-1β), and histopathological analysis. Survival rates were also determined. Mice treated with IRI had a significantly (p < 0.05) lower survival rate than controls and time- and dose-dependent body weight loss. ALT and AST plasma levels increased in relation to controls only in mice receiving IRI 50 mg/kg (p < 0.05). The histopathological features characteristic of NASH was observed, including steatosis, lobular neutrophil infiltration and ballooning hepatocytic degeneration. Additional findings included increased MPO, lipid accumulation, portal neutrophil infiltration, IL-1β and iNOS expression and fibrosis in liver tissues and low serum protein levels compared to controls. This is the first report of a consistent model of IRI-induced NASH capable of mimicking clinical findings.
- 1 August 2014
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (4) , 711-720
Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model
Nonalcoholic steatohepatitis (NASH) has been associated with irinotecan (IRI)-based cancer chemotherapy regimens. The purpose of this study was to propose and test a consistent model of IRI-induced NASH, filling a gap in the medical literature. Swiss male mice were distributed in groups (n = 8) and injected with saline (5 mL/kg, i.p.; control) or IRI (25, 50, 75 or 100 mg/kg, i.p.) thrice a week for 7 weeks. Blood samples were collected to measure the serum concentrations of proteins, alanine and aspartate aminotransferases (ALT and AST). Each week animals were euthanized, and the livers were submitted to myeloperoxidase (MPO) assay, lipid dosage, immunohistochemistry for inducible nitric oxide synthase (iNOS), TNF-α and interleukin-1β (IL-1β), and histopathological analysis. Survival rates were also determined. Mice treated with IRI had a significantly (p < 0.05) lower survival rate than controls and time- and dose-dependent body weight loss. ALT and AST plasma levels increased in relation to controls only in mice receiving IRI 50 mg/kg (p < 0.05). The histopathological features characteristic of NASH was observed, including steatosis, lobular neutrophil infiltration and ballooning hepatocytic degeneration. Additional findings included increased MPO, lipid accumulation, portal neutrophil infiltration, IL-1β and iNOS expression and fibrosis in liver tissues and low serum protein levels compared to controls. This is the first report of a consistent model of IRI-induced NASH capable of mimicking clinical findings.